

Effective as of 1 December 2022 Raiffeisen Centrobank AG has transferred its certificates business to Raiffeisen Bank International AG including (i) all associated rights and obligations, and (ii) the legal position as issuer of existing securities, i.e. outstanding securities issued by Raiffeisen Centrobank AG. Therefore, as of 1 December 2022, Raiffeisen Bank International AG constitutes the issuer of and the debtor under the securities referred to in the product brochure.

Please be aware that the product brochure reflects the legal situation at the date of its creation and does not contain any updated information about the issuer.

PHARMA STOCKS BOND

INVESTMENT PRODUCT WITH CAPITAL PROTECTION GUARANTEE CERTIFICATE

- OPPORTUNITY FOR AN ANNUAL INTEREST RATE OF 4%
- STOCK BASKET AS UNDERLYING: ASTRAZENECA PLC, NOVARTIS AG AND SANOFI SA
- 100% CAPITAL PROTECTION AT THE END OF THE TERM
- OPPORTUNITIES/RISKS ON THE FOLLOWING PAGES
- 8 YEAR TERM



ATTRACTIVE INTEREST OPPORTUNITY, CAPITAL PROTECTION In short:

Raffeisen Centrobank's Guarantee Certificate Pharma Stocks Bond provides investors with the annual opportunity to obtain an interest rate of 4%. The performance of the three underlying shares determines whether the interest amount will be paid out. In case of a negative performance the capital protection of 100% applies at the end of the term (June 2024).

KEY FACTS

Issuer	Raiffeisen Centrobank AG		
Guarantor*	Raiffeisen Centrobank AG		
ISIN	AT0000A1N979		
Issue price	100%		
	plus 3% issue surcharge		
W	vithin the subscription period		
Nominal value	EUR 1,000		
Subscr. period ¹	Aug 5 - Sep 9, 2016		
Initial valuation	date Sep 12, 2016		
Issue value date	Sep 13, 2016		
Final valuation of	l '		
Maturity date	Sep 16, 2024		
Capital protection	on 100% (end of term)		
Interest rate opp	ortunity 4% annually		
Starting value	closing price of each share		
	at the initial valuation date		
Observation	annually (closing price)		
on the respective valuation date			
Annual valuation dates Sep 11, 2017;			
Sep 11, 2018; Sep 11, 2019; Sep 11, 2020;			
Sep 13, 2021; S	Sep 12, 2022; Sep11, 2023;		
	Sep 11, 2024		
	out dates Sep 14, 2017;		
	ep 16, 2019; Sep 16, 2020;		
Sep 16, 2021; S	Sep 15, 2022; Sep14, 2023;		
	Sep 16, 2024		
Redemption	The certificate is		
	00% of the nominal value at		
the maturity date. (redemtion is dependant			
	of Raiffeisen Centrobank*).		
Listing	Vienna, Frankfurt, Stuttgart		

^{*} Raiffeisen Centrobank AG is a 100% owned subsidiary of Raiffeisen Bank International AG – rating of RBI: www.rbinternational.com/ir/ratings

www.rcb.at

Quotes

Currently there is hardly any sector demonstrating such a dynamic performance as the **pharmaceutical and healthcare sector**. The increasingly aging society reveals a demographic change in numerous industrialised and threshold countries. As a result investors have been focusing more and more on innovative pharmaceutical companies. In line with this trend Raiffeisen Centrobank has issued the **Pharma Stocks Bond**.

The underlying stock basket consists of three blue chips of the pharmaceutical industry: AstraZeneca PLC, Novartis AG and Sanofi SA. Investors who expect these blue chips to perform stably can realize their market opinion with an investment in the Pharma Stocks Bond Guarantee Certificate. The certificate with full capital protection at the end of the term is suited to security-oriented investors who want to capitalize on a sideways moving or slightly rising market. Taking the issue surcharge of 3% during the subscription period into account, the maximum return comes up to 3.56% p.a. Further details regarding opportunities and risks are presented on the following page. The certificate's term is eight years.

FUNCTIONALITY

At the initial valuation date, the **starting values of all three underlying shares** (closing price of each share) are determined. During the observation period, the **current closing price** of each share is compared with its respective starting value at each annual valuation date. One of the following **two scenarios** will occur:

SCENARIO 1: All three shares quote AT or ABOVE their respective starting value at the annual valuation date


Provided that the closing prices of AstraZeneca PLC, Novartis AG **AND** Sanofi SA are at or above their respective starting value at the annual valuation date, the investor obtains the interest rate of 4% (equals EUR 40 per EUR 1,000 nominal value). Investors have the opportunity to obtain the interest rate of 4% again in the follwing years of the term.

SCENARIO 2: ONE or MULTIPLE underlying shares quote BELOW their respective starting value at the annual valuation date

In case the closing price of one share or multiple shares quotes below the respective starting value at the current annual valuation date, no interest will be paid out for the respective year. However, investors have the opportunity to obtain the interest rate of 4% again in the follwing years of the term, and can still benefit from a positive share performance.

At the end of the term the investment is 100% capital protected by Raiffeisen Centrobank, i.e. during the term price fluctuations may occur, but investors obtain at least 100% of the nominal value at the end of the term.

¹ Early closing or extension of the subscription period is within the sole discretion of Raiffeisen Centrobank AG.



AstraZeneca Group is active in research and manufacturing of pharmaceutical and medical products in eight therapy areas: gastrointestinal, oncology, neuroscience, palliative, anaesthesia, infection, respiratory and cardiac diseases. The company is headquartered in London and generated total revenue of USD 24.7 bn in 2015.

(Source: AstraZeneca Annual Report and Form 20-F Information 2015)

Novartis is a global healthcare company based in Switzerland. In 2015, the company generated net sales of USD 49.4 bn. Novartis is active in a wide variety of medical fields and comprises various brands including

Sanofi SA

Sanofi is a global life sciences company, headquartered in Paris. In 2015, the company generated aggregate group sales of USD 37.1 bn and accounts for one of the heavyweights in the industry. The company's business includes therapeutic solutions in the fields of diabetes, oncology and cardiovascular diseases as well as vaccines.

(Source: www.sanofi.com)


Please note that past performances do not allow any inferences to be made about future performances of the underlying indices.

TAXATION

Exempt from EU withholding tax

For EU citizens not tax-liable in Austria revenue obtained with the Certificate is not subject to EU withholding tax. Exemption from EU withholding tax is based on current legislation and cannot be guaranteed for the full term of the product.

YOUR EXPECTED MARKET TREND



YOUR INVESTMENT HORIZON



NOTE

The mentioned opportunities and risks display a summary of the most important facts regarding the product.

For further information see the prospectus (including possible changes and additions) - approved by the Austrian Financial Market Authority, deposited at the Oesterreichische Kontrollbank AG and published on: www.rcb.at/securitiesprospectus

OPPORTUNITIES

Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2013 | 2014 | 2015

Yield opportunity in sideways moving markets:

Even with sideways moving or slightly increasing prices of the three underlying shares investors can generate a solid yield.

100% capital protection at the end of the term:

The Guarantee Certificate Pharma Stocks Bond is 100% capital protected at the end of the term (September 2024), i.e. the investor obtains at least the nominal value.

Secondary market:

Flexibility through tradability on the secondary market, no management fees

RISKS

No yield when shares perform negatively

In case the performance of at least one of the three underlying shares is negative at the annual valuation date, the investor obtains no interest rate in the respective year of the term.

Price fluctuations during the term:

During the term the price of the certificate may drop below 100%, the capital protection takes effect exclusively at the end of the term. Loss of value due to inflation is not covered by the capital protection.

Redemption is dependent on the solvency of Raiffeisen Centrobank AG (issuer risk). In case of insolvency of the issuer the investor may incur a total loss.

DISCLAIMER

In spite of careful research, the information contained in this marketing communication serves only for the information of our customers without commitment on our part. In particular this marketing communication is not an investment recommendation or financial analysis

The information does neither constitute an investment advice nor a recommendation nor a solicitation to conclude any transaction. Equally, the information contained in this brochure cannot substitute investor or investment specific advice. The sole legal basis for all products described in this brochure is the base prospectus (including any possible changed or supplemented information) which has been approved by the Austrian Financial Market Authority, in connection with the Final Terms all of which have been deposited at the Oesterreichische Kontrollbank AG. These documents and further information, respectively, are provided on the website of Raiffeisen Centrobank AG at www.rcb.at.

Unless otherwise explicitly expressed in any of the documents cited above no measures were or are taken in any national legal system, which should permit a public offering of the products described herein. Raiffeisen Centrobank AG explicitly excludes any liability regarding this brochure, in particular in relation to the correctness, appropriateness and completeness of the information presented herein.

During the term the market price of the certificate may drop below 100% of the issue price due to price fluctuations. The capital guarantee of 100% nominal value exclusively applies to the maturity date. The market price of the certificate needs not develop simultaneously to the market price of the underlying during the term. During the term the market price of the certificate is subject to various influencing factors such as volatility, coupon rate, credit rating of the issuer and time to maturity date. Redemption or repayment of the certificate at maturity is dependent on the solvency of the issuer. Further information – see Prospectus.

The information presented does not constitute a binding tax advice. Taxation of investments is dependent on the personal situation of the investor and may be subject to change. As regards taxation and impact on the investor's individual tax situation, it is recommended to consult a tax advisor. This report is based on the knowledge the person preparing the document has obtained up to the creation date. Please note that the legal situation may change due to legislative amendments, tax directives, opinions of financial authorities, jurisdiction etc.

Supervisory Authorities: Raiffeisen Centrobank AG is subject to the regulatory supervision of the Federal Finance Ministry, the Austrian National Bank, as well as the Financial Market Supervisory Authority and all government laws and regulations, especially those of the Austrian Banking Act (BWG) and the Securities Regulation Act (RWAG). Additionally, Raiffeisen Centrobank AG is subject to supervision by the European Central Bank (ECB), which ECB undertakes within the Single Supervisory Mechanism (SSM), which consists of the ECB and the national responsible authorities (Council Regulation (EU) No 1024/2013 of the Council of the European Union).

Imprint ("Impressum") pursuant to Austrian Media Act media owner and producer Raiffeisen Centrobank AG, Tegetthoffstrafle 1, 1015 Wien.

Further information may be obtained from the consultant at your local bank, on the Internet at www.rcb.at or through the product hotline of Raiffeisen Centrobank: +43 (0)1 51520 - 484.

Your Contacts at Raiffeisen Centrobank AG, A-1015 Vienna, Tegetthoffstrasse 1:

Product Hotline	Ph.: +43 1/51520 - 484	produkte@rcb.at
Heike Arbter (Head of Structured Products)	Ph.: +43 1/51520 - 407	heike.arbter@rcb.at
Philipp Arnold	Ph.: +43 1/51520 - 469	philipp.arnold@rcb.at
Roman Bauer	Ph.: +43 1/51520 - 384	roman.bauer@rcb.at
Walter Friehsinger	Ph.: +43 1/51520 - 392	walter.friehsinger@rcb.at
Anna Gaszynska	Ph.: +43 1/51520 - 404	anna.gaszynska@rcb.at
Marianne Koegel	Ph.: +43 1/51520 - 482	marianne.koegel@rcb.at
Jaroslav Kysela	Ph.: +43 1/51520 - 481	jaroslav.kysela@rcb.at
Thomas Mairhofer	Ph.: +43 1/51520 - 395	thomas.mairhofer@rcb.at
Aleksandar Makuljevic	Ph.: +43 1/51520 - 385	aleksandar.makuljevic@rcb.at
Monika Mustikova	Ph.: +43 1/51520 - 387	monika.mrnustikova@rcb.at
Stefan Neubauer	Ph.: +43 1/51520 - 486	stefan.neubauer@rcb.at
Premysl Placek	Ph.: +43 1/51520 - 394	premysl.placek@rcb.at
Clemens Puehringer	Ph.: +43 1/51520 - 391	clemens.puehringer@rcb.at
Ludwig Schweighofer	Ph.: +43 1/51520 - 460	ludwig.schweighofer@rcb.at
Thomas Stagl	Ph.: +43 1/51520 - 351	thomas.stagl@rcb.at
Alexander Unger	Ph.: +43 1/51520 - 478	alexander.unger@rcb.at
Martin Vonwald	Ph.: +43 1/51520 - 338	martin.vonwald@rcb.at



